Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 5/20 | 0.73 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.55 |
| ▸ | WHR1 | P49842 | 6/20 | 0.53 |
| ▸ | CCR4 | P51679 | 2/20 | 0.51 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31016435 | 1.00 | NSD2 (0.73) | NSD2EHMT2WHR1CCR4DNMT3A | |
| SCHEMBL31016453 | 0.91 | NSD2 (0.73) | NSD2EHMT2WHR1CCR4DNMT3A | |
| SCHEMBL31016448 | 0.84 | EHMT2 (0.77) | NSD2EHMT2WHR1CCR4EHMT1 | |
| SCHEMBL22144764 | 0.84 | EHMT2 (0.77) | NSD2EHMT2WHR1CCR4EHMT1 | |
| SCHEMBL31016443 | 0.84 | EHMT2 (0.77) | NSD2EHMT2WHR1CCR4EHMT1 | |
| SCHEMBL31016439 | 0.84 | NSD2 (1.00) | NSD2EHMT2EHMT1 | |
| SCHEMBL31016449 | 0.82 | WHR1 (0.74) | NSD2EHMT2WHR1 | |
| SCHEMBL21486538 | 0.81 | DNMT3A (0.74) | NSD2EHMT2DNMT3AEHMT1 | |
| SCHEMBL25361908 | 0.81 | EHMT2 (0.65) | NSD2EHMT2WHR1CCR4EHMT1 | |
| SCHEMBL30546992 | 0.77 | NSD2 (0.70) | NSD2EHMT2WHR1CCR4EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322643-A1 | HISTONE DEACETYLASE AND HISTONE METHYLTRANSFERASE INHIBITORS AND METHODS OF MAKING AND USE OF THE SAME | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322643-A1 | HISTONE DEACETYLASE AND HISTONE METHYLTRANSFERASE INHIBITORS AND METHODS OF MAKING AND USE OF THE SAME | HDAC1, HDAC2, DOT1L | NSD2 95/4885EHMT2 4/4885WHR1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.